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Previous studies from our laboratory have shown that the transmembrane domain (TM) of the Vpu protein of human immunodeficiency virus
type 1 (HIV-1) contributes to the pathogenesis of SHIVKU-1bMC33 in macaques and that the TM domain of Vpu could be replaced with the M2
protein viroporin from influenza A virus. Recently, we showed that the replacement of the TM domain of Vpu with that of the M2 protein of
influenza A virus resulted in a virus (SHIVM2) that was sensitive to rimantadine [Hout, D.R., Gomez, M.L., Pacyniak, E., Gomez, L.M., Inbody,
S.H., Mulcahy, E.R., Culley, N., Pinson, D.M., Powers, M.F., Wong, S.W., Stephens, E.B., 2006. Substitution of the transmembrane domain of
Vpu in simian human immunodeficiency virus (SHIVKU-1bMC33) with that of M2 of influenza A results in a virus that is sensitive to inhibitors of
the M2 ion channel and is pathogenic for pig-tailed macaques. Virology 344, 541–558]. Based on previous studies of the M2 protein which have
shown that the His–X–X–X–Trp motif within the M2 is essential to the function of the M2 proton channel, we have constructed a novel SHIV in
which the alanine at position 19 of the TM domain was replaced with a histidine residue resulting in the motif His–Ile–Leu–Val–Trp. The
SHIVVpuA19H replicated with similar kinetics as the parental SHIVKU-1bMC33 and pulse-chase analysis revealed that the processing of viral
proteins was similar to SHIVKU-1bMC33. This SHIVVpuA19H virus was found to be more sensitive to the M2 ion channel blocker rimantadine than
SHIVM2. Electron microscopic examination of SHIVVpuA19H-infected cells treated with rimantadine revealed an accumulation of viral particles at
the cell surface and within intracellular vesicles, which was similar to that previously observed to SHIVM2-infected cells treated with rimantadine.
These data indicate that the Vpu protein of HIV-1 can be converted into a rimantadine-sensitive ion channel with the alteration of one amino acid
and provide additional evidence that drugs targeting the Vpu TM/ion channel can be effective anti-HIV-1 drugs.
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The Vpu protein is the smallest membrane protein encoded
by human immunodeficiency virus type 1 (HIV-1) and consists
of a short amino terminal domain, an uncleaved signal
sequence-transmembrane (TM) domain, and a cytoplasmic
domain consisting of two α-helices and two highly conserved
casein kinase sites (Strebel et al., 1988; Cohen et al., 1988;
Schubert et al., 1994, McCormick-Davis et al., 2000a; Hout et
al., 2004a). Previous studies have shown that the Vpu protein⁎ Corresponding author. Fax: +1 913 588 2710.
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doi:10.1016/j.virol.2005.12.025has at least two functions within HIV-1-infected cells. The first
of these functions involves the interaction of Vpu with the CD4
molecule and subsequent targeting of CD4 to the proteasome
for degradation (Fujita et al., 1997; Schubert et al., 1998). Both
α-helices as well as the highly conserved casein kinase II sites
(CK-II) in the cytoplasmic domain have been implicated in CD4
down-regulation (Schubert et al., 1996b; Paul and Jabbar, 1997;
Tiganos et al., 1998). The second function associated with the
Vpu protein is the ability to enhance virion release from infected
cells (Klimkait et al., 1990). While the exact mechanism of
enhanced virion release is unknown, some studies have
associated this property with the TM of Vpu (Schubert et al.,
1996a). The TM of Vpu has been shown to form ion channels
Fig. 1. Sequence of the proteins analyzed in this study. Shown are the sequence of the Vpu, VpuA19H, and VpuM2 proteins.
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monovalent anions when expressed in frog oocytes (Ewart et
al., 1996; Schubert et al., 1996a). This ion channel activity was
localized to the TM domain and appears to be independent from
the cytoplasmic domain in enhancing viral release from cells
(Schubert et al., 1996b). More recently, drugs have been
identified that interfere with the Vpu-mediated virion release
from cells (Ewart et al., 2002, 2004).
Recently, we showed that the transmembrane domain of Vpu
could be replaced with the TM domain of the M2 protein of
influenza A virus (Hout et al., 2006). This virus, SHIVM2, was
capable of causing a severe loss of CD4+ T cells and AIDS
when inoculated into macaques. In addition, we found that
unlike the parental SHIVKU-1bMC33, replication of the SHIVM2
virus was sensitive to an M2 ion channel blocker rimantadine.
This study showed that drugs targeting the TM domain of VpuFig. 2. VpuEGFPA19H is expressed in the same intracellular compartments as
VpuEGFP or VpuA19H EGFP and DsRed2-ER or ECFP-Golgi. At 48 h, cells expre
laser scanning confocal microscopy as described in the Materials and methods s
Expression of VpuEGFP. (B) Expression of DsRed2-ER. (C) Merge of panels A an
panels A and B. (E–H) 293 cells co-transfected with VpuEGFP and ECFP-Golgi
panels E and F. (H) Fluorescence micrograph of EGFP and ECFP fusion pr
VpuEGFPA19H and ECFP-Golgi. (I) Expression of VpuEGFPA19H. (J) Expressio
of EGFP and ECFP fusion proteins from panels I and J.(in this case, a chimeric Vpu with the TM of M2 protein) could
reduce virus release from infected cells. Previous studies of the
M2 protein have shown that the His–X–X–X–Trp motif within
the TM domain was essential for ion channel activity and
inhibition by amantadine, another M2 ion channel blocker
(Okada et al., 2001; Tang et al., 2002; Takeuchi et al., 2003).
Alteration of the histidine residue within the M2 TM domain to
an alanine resulted in a constitutively open channel, indicating
its importance to channel activation (Holsinger and Lamb,
1991; Holsinger et al., 1994; Pinto et al., 1992; Tang et al.,
2002). Interestingly, the subtype B Vpu contains the sequence
Ala–X–X–X–Trp in approximately the same position in the
Vpu TM, with the tryptophan being invariant (McCormick-
Davis et al., 2000a). In the present study, we have substituted
the alanine in this motif with a histidine residue. We show that
the replication of a SHIV (SHIVVpuA19H) expressing this mutantthe wild type Vpu. 293 cells were co-transfected with vectors expressing
ssing EGFP and DsRed2 or ECFP were identified and images collected using
ection. (A–D) 293 cells co-transfected with VpuEGFP and DsRed2-ER. (A)
d B. (D) Fluorescence micrograph of EGFP and DsRed2 fusion proteins from
. (E) Expression of VpuEGFP. (F) Expression of ECFP-Golgi. (G) Merge of
oteins from panels E and F. (I–L) HeLa CD4+ cells co-transfected with
n of ECFP-Golgi. (K). Merge of panels I and J. (L) Fluorescence micrograph
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virus. These results indicate that a single amino acid substitution
in Vpu protein converts a rimantadine-resistant to a rimanta-
dine-sensitive SHIV and provides additional in vivo evidence
that the Vpu TM domain is a potential target for anti-HIV1
drugs.
Results
The VpuA19H protein is transported to the same intracellular
compartment as the unmodified Vpu protein
The sequences of the Vpu protein and the VpuA19H mutant
are shown in Fig. 1. We analyzed the intracellular transport of
the VpuA19H protein by fusion to the enhanced green
fluorescent protein (EGFP) (Singh et al., 2003; Pacyniak et
al., 2005). Co-transfection of 293 cells with the vectors
expressing the unmodified subtype B Vpu protein (VpuEGFP)
and DsRed2-ER resulted in this protein being partially co-
localized with this intracellular marker (Figs. 2A–D). Co-
transfection with the vectors expressing the unmodified
subtype B protein (VpuEGFP) and ECFP-Golgi resulted in
nearly complete co-localization (Figs. 2E–H). Co-transfectionFig. 3. CD4 down-regulation by EGFP, VpuEGFP, and VpuEGFPA19H. HeLaCD
VpuEGFP, or VpuEGFPA19H. At 48 h post-transfection, cells were stained for surfa
followed by fixation with 1% formalin. Cells were examined by laser scanning confo
expressing the EGFP and VpuEGFP fusion proteins and layered onto a phase contra
CD4 expression and layered onto a phase contrast image of the cell. (C, G, and K) C
expression and layered onto a phase contrast image of the cell. Vpu fusion proteins. (
and CD4 expression). (A–D) Cells transfected with a vector expressing EGFP. (E–H
with a vector expressing VpuEGFPA19H.of 293 cells with the vectors expressing VpuA19HEGFP and
ECFP-Golgi resulted in the two proteins being almost
completely co-localized (Figs. 2I–L). Similar to unmodified
protein, co-transfection of 293 cells with a vector expressing
the VpuEGFPA19H and either DsRed2-ER or ECFP-Mem
markers revealed partial co-localization with the VpuEGFP-
A19H but did not appear to be transported to the cell surface
(data not shown). These results indicate that the VpuA19H
protein was transported to the same intracellular compartment
as the unmodified Vpu protein and correlates well with our
recent study that identified the cytoplasmic domain as having a
Golgi retention signal (Pacyniak et al., 2005).
The VpuEGFPA19H is capable of down-regulating cell surface
CD4
We determined if the VpuEGFPA19H was capable of
preventing cell surface expression of CD4. HeLaCD4+ cells
were transfected with vectors expressing EGFP, VpuEGFP,
and VpuEGFPA19H. At 48 h post-transfection, live cells
were stained for cell surface CD4, fixed, and examined by
confocal microscopy. As shown in Figs. 3A–D, expression of
EGFP did not prevent CD4 expression while transfection of4+ cells, which express CD4, were transfected with vectors expressing EGFP,
ce CD4 using α-CD4 antibody and a rhodamine-conjugated secondary antibody
cal microscopy. (A, E, and I) Cells were examined using a filter to identify cells
st image of the cell. (B, F, and J) Cells were examined using a filter to visualize
ells were examined using filters to identify cells expressing the EGFP and CD4
D, H, and L) Fluorescent micrographs with dual filters (for expression of EGFP
) Cells transfected with a vector expressing VpuEGFP. (I–L) Cells transfected
Fig. 5. Immunoprecipitation of Vpu proteins and p27 growth curves of
SHIVVpuA19H and SHIVKU-1bMC33 in C8166 cells is similar to the parental
SHIVKU-1bMC33. (A) C8166 cells were inoculated with SHIVKU-1bMC33 or
SHIVVpuA19H and incubated for 6 days. Cells were starved for methionine/
cysteine and then radiolabeled with 35S-methionine/cysteine for 12 h. Cell
lysates were prepared and Vpu proteins immunoprecipitated as described
in the Materials and methods section. Lane 1: Vpu proteins immunopre-
cipitated from uninfected cells. Lane 2: Vpu proteins immunoprecipitated
from SHIVVpuA19H inoculated cultures. Lane 3: Vpu proteins immunopre-
cipitated from SHIVKU-1bMC33-inoculated cultures. (B) Growth curves of
SHIVKU-1bMC33 (■) and SHIVVpuA19H (●) in C8166 cells. Cultures of
C8166 cells were inoculated with either SHIVKU-1bMC33 or SHIVVpuA19H as
described in the Materials and methods section. Aliquots of the culture
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prevented cell surface expression (Figs. 3E–H), which was
similar to what we previously reported (Pacyniak et al.,
2005; Singh et al., 2003). Transfection of HeLaCD4+ cells
with the vector expressing VpuEGFPA19H also prevented
cell surface expression of CD4 (Figs. 3I–L) and was similar
to the unmodified VpuEGFP. In addition, we performed co-
transfection experiments with vectors expressing EGFP,
VpuEGFP, or VpuEGFPA19H and human CD4 in the
absence or presence of rimantadine. The results confirmed
that the VpuEGFP and VpuEGFPA19H induced CD4
degradation while CD4 was stably expressed in the presence
of EGFP (Fig. 4). Rimantadine treatment during the chase
period did not appear to influence CD4 degradation in this
assay. Together, these results indicate that replacement of the
alanine in Vpu TM domain with a histidine residue did not
affect the ability of Vpu to induce degradation of CD4.
SHIVVpuA19H expresses a Vpu protein with the same Mr as the
unmodified protein and replicates with similar kinetics
compared to parental SHIVKU-1bMC33
We determined if the SHIVVpuA19H expressed a protein with
a similar Mr as the parental SHIVKU-1bMC33 virus. C8166 cells
were inoculated with either SHIVVpuA19H or SHIVKU-1bMC33 for
6 days and then radiolabeled for 12 h with 35S-methionine/
cysteine. Cell lysates were prepared and Vpu proteins
immunoprecipitated using an anti-Vpu serum. As shown in
Fig. 5A, Vpu proteins with a similar Mr were immunoprecipi-
tated from C8166 cells inoculated with SHIVKU-1bMC33 or
SHIVVpuA19H but not from uninoculated C8166 cells. InFig. 4. The VpuEGFPA19H fusion protein induces degradation of human CD4.
293 cells were transfected with vectors expressing human CD4 and either EGFP,
VpuEGFP, or VpuEGFPA19H in the presence or absence of rimantadine. At 48
h post-transfection, cells were starved for methionine and cysteine and
radiolabeled with 35S-methionine/cysteine for 5 h. Rimantadine (50 μM) was
added during the chase period. Cell lysates were prepared in 1× RIPA buffer and
the CD4 proteins immunoprecipitated using a rabbit anti-human CD4 antibody
and protein A Sepharose (PAS). The immunoprecipitates were washed, boiled in
sample reducing buffer, and analyzed by SDS-PAGE (10% gel). Lane 1: Non-
transfected 293 cells. Lane 2: CD4 proteins immunoprecipitated from cells co-
transfected with vectors expressing human CD4 and VpuEGFPA19H in the
presence of rimantadine. Lane 3: CD4 proteins immunoprecipitated from cells
co-transfected with vectors expressing human CD4 and VpuEGFPA19H. Lane
4: CD4 proteins immunoprecipitated from cells co-transfected with vectors
expressing human CD4 and VpuEGFP in the presence of rimantadine. Lane 5:
CD4 proteins immunoprecipitated from cells co-transfected with vectors
expressing human CD4 and VpuEGFP. Lane 6: CD4 proteins immunopreci-
pitated from cells co-transfected with vectors expressing human CD4 and EGFP
in the presence of rimantadine. Lane 7: CD4 proteins immunoprecipitated from
cells co-transfected with vectors expressing human CD4 and EGFP.
medium were assayed for the presence of p27 antigen. The growth curves
were performed in triplicate.addition to the pulse-labeling experiment in Fig. 5A, p27
growth curves were performed to quantify the amount of virus
released. Cultures of C8166 cells were inoculated with an
equivalent dose (10 ng) of infectious SHIVKU-1bMC33 or
SHIVVpuA19H. Culture media were collected at 0, 1, 3, 5, 7,
and 10 days post-inoculation and assayed for p27 release. As
shown in Fig. 5B, growth curves revealed that the kinetics of
viral p27 released into the culture medium were similar to the
parental SHIVKU-1bMC33. In addition, we neither observed
differences in the appearance of syncytial cytopathology nor in
the extent of syncytia formation.
Pulse-chase analysis reveals that SHIVVpuA19H and parental
SHIVKU-1bMC33 process proteins with similar kinetics
We examined the processing of the Env and Gag
precursors in C8166 cells inoculated with SHIVKU-1bMC33 or
SHIVVpuA19H at 7 days by pulse-chase analyses (Fig. 6). Fig.
6A shows normal synthesis and processing of precursor
proteins from parental SHIVKU-1bMC33, and Fig. 6C shows the
SHIVKU-1bMC33 proteins released into the culture medium. As
shown in Fig. 6C, Gag proteins were released into the culture
medium starting at the 1 h chase period, similar to what we
Fig. 6. Pulse-chase analysis reveals that viral proteins released from SHIVVpuA19H-inoculated cells occur with similar kinetics to parental SHIVKU-1bMC33. Cultures of
C8166 cells were inoculated with SHIVKU-1bMC33 or SHIVVpuA19H as described in the Materials and methods section. At 7 days post-infection, infected cells were
starved for methionine and then pulse labeled with 1 mCi of 35S-methionine and cysteine for 30 min. The medium containing the radiolabel was removed, washed once
with medium containing 100× cold methionine and cysteine, and the radiolabel chased for various periods of time (0, 1, 2, 4, and 6 h). The culture medium was
collected and cell lysates prepared as described in the text. SHIV-specific proteins were immunoprecipitated using a pooled serum from 4 macaques that had been
infected with non-pathogenic SHIV for 6 months. SHIV-specific proteins from the cell lysates from SHIVKU-1bMC33-inoculated and SHIVVpuA19H-inoculated C8166
cultures are shown in panels A and B, respectively. SHIV-specific proteins from the culture medium from SHIVKU-1bMC33-inoculated and SHIVVpuA19H-inoculated
C8166 cultures are shown in panels C and D, respectively. Uninfected C8166 cells, radiolabeled and chased for 6 h, served as a negative control (lanes C). All samples
were analyzed under reducing conditions by SDS-PAGE (10% gel) and visualized by standard autoradiographic techniques.
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Stephens et al., 2002). The results of the pulse-chase analysis
of SHIVVpuA19H-infected cells are shown in Figs. 6B–D. The
Env and Gag precursors appeared to be processed with similar
kinetics as that observed for the parental SHIVKU-1bMC33 (Fig.
6B). As shown in Fig. 6D, viral Gag proteins were detected in
the culture medium beginning at the 1 h chase period. These
results indicate that the release of viral proteins virus from
SHIVVpuA19H-inoculated cultures was similar to the parental
virus.
The replication of SHIVVpuA19H is more sensitive to
rimantadine than SHIVM2
Previously, we showed that, when the TM domain of Vpu
was replaced with that of the M2 protein of influenza A
virus, the virus became sensitive to the drug rimantadine
between 50 and 100 μM (Hout et al., 2006). We determinedif SHIVVpuA19H was sensitive to rimantadine. C8166 cells
were inoculated with equivalent doses of SHIVVpuA19H or
parental SHIVKU-1bMC33 for 4 h, the inoculum removed by
washing cells and then incubated with various concentrations
(0, 10 25, 50, 75, or 100 μM) of rimantadine. At 7 days
post-inoculation, culture media were retained for p27
measurement and the cells radiolabeled overnight with 35S-
methionine/cysteine. Viral proteins were immunoprecipitated
from the culture medium and from cell lysates. As shown in
Figs. 7A–B, the addition of rimantadine to SHIVKU-1bMC33-
inoculated cultures did not affect the release of p27 antigen
in the culture supernatants or the synthesis of viral proteins.
In contrast, the addition of rimantadine to SHIVVpuA19H-
inoculated cultures reduced p27 release into the culture
medium in a dose-dependent manner by an average of 20%
at 25 μM and 87% at 50 μM to N99% for 75 and 100 μM
(Fig. 7A). In addition, SHIVVpuA19H appeared to be more
sensitive to rimantadine than SHIVM2. The sensitivity of
Fig. 7. Rimantadine interferes with the replication and spread of SHIVVpuA19H and SHIVM2 but not parental SHIVKU-1bMC33. (A) C8166 cells were inoculated with
either SHIVVpuA19H, SHIVM2, or SHIVKU-1bMC33 in the presence of various concentrations of rimantadine or in the absence of rimantadine. At 7 days post-inoculation,
culture supernatant was removed, clarified, and assayed for the presence of p27 antigen. The numbers above the bars represent the range and the mean percentage of
p27 released compared to the control. (B and C) At 7 days post-inoculation, untreated or treated cells were starved for methionine and cysteine and radiolabeled
overnight with 35S-methionine/cysteine for 12 h. Viral proteins were immunoprecipitated from the culture medium as described in the Materials and methods section
from SHIVKU-1bMC33 (B) or SHIVVpuA19H (C).
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to immunoprecipitate viral proteins from the culture medium
(Fig. 7C).
Electron microscopy reveals that rimantadine-treated C8166
cells infected with SHIVVpuA19H accumulate viral particles at
the cell surface and within intracellular membranes
As our inhibitor studies indicated that rimantadine inhibited
the replication of the SHIVVpuA19H, we examined the
maturation of the SHIVVpuA19H and parental SHIVKU-1bMC33
in the presence of 25 μM rimantadine. We chose to examine
infected cells treated with 25 μM rimantadine as this was a
concentration that showed partial (∼80%) inhibition of
SHIVVpuA19H release as determined by p27 assays and that
this concentration of rimantadine is not toxic to cells.
Previously, we showed that parental SHIVKU-1bMC33 maturedat the cell surface and that 50 μM rimantadine did not appear
to affect virus maturation (Hout et al., 2006). The maturation
of SHIVVpuA19H was similar to SHIVKU-1bMC33 in the absence
of rimantadine (Fig. 8A). Electron microscopy revealed that
the mean number of viral particles per cell was 47 and 45 for
untreated and 50 μM treated SHIVKU-1bMC33-inoculated
cultures, with the majority of the cells having less than 50
viral particles per cell (Figs. 9C–D). However, maturation of
SHIVVpuA19H was considerably altered in the presence of 25
μM rimantadine. As shown in Figs. 8B–D, virus particles
appeared to accumulate at the cell surface and within
intracellular vesicles. The mean number of viral particles
per cell was 39 for untreated SHIVVpuA19H-inoculated C8166
cells, while the mean number of particles per cell was 94 in
25 μM rimantadine-treated SHIVVpuA19H-inoculated cells,
over twice that observed for the untreated cells (Figs. 9A–
B). These results suggest that SHIVVpuA19H release from
Fig. 8. Electron microscopic examination of C8166 cells inoculated with SHIVVpuA19H in the absence or presence of rimantadine. C8166 cells were inoculated with
SHIVVpuA19H for 7 days. Cells were washed three times with PBS and processed for electron microscopy as described in the Materials and methods section. (A)
Untreated C8166 cells inoculated with SHIVVpuA19H. (B–D) C8166 cells inoculated with SHIVVpuA19H in the presence of 25 μM rimantadine.
455D.R. Hout et al. / Virology 348 (2006) 449–461infected cells was abrogated in the presence of 25 μM
rimantadine.
Discussion
The M2 protein of influenza A virus is the prototypic
member of a class of viral proteins with ion channel activity
known as viroporins, which also includes the BM2 protein of
influenza B virus, the 6K protein of Sindbis virus (SV), and the
2B protein of poliovirus and the Vpu protein of HIV-1
(Gonzalez and Carrasco, 2003). The Vpu protein of HIV-1
has been modeled after the M2 protein of influenza A virus as
they have a similar orientation within the membrane, similar
length, and the ability to form an oligomeric structure (Klimkait
et al., 1990; Grice et al., 1997; Lamb and Pinto, 1997; Sansom
et al., 1998; Cordes et al., 2001, 2002; Fischer and Sansom,
2002; Hout et al., 2004a). The ion channel of M2 protein
involves the formation of a homotetrameric structure. The
amino acid residues that line the pore (Ala30, Gly34, His37, and
Trp41) have been identified by cysteine-scanning mutagenesis
and inhibition with transition elements (Gandhi et al., 1999;
Shuck et al., 2000). Of these residues, the His37 residue is
thought to act as both the pH sensor and selectivity filter, while
the Trp41 serves as the activation gate (Tang et al., 2002). Thus,
the His–X–X–X–Trp motif in the M2 ion channel is critical for
proper functioning of the proton ion channel. The M2 ionchannel is sensitive to the actions of the polycyclic amines
amantadine and rimantadine. Both amantadine and rimantadine
act as surrogate proton donors. However, treatment of patients
with amantadine generally results in the selection of amanta-
dine-resistant escape mutants, and these mutations generally
occur at the pore-lining residues (Hay et al., 1986). Viral
resistance to these drugs is thought to occur by two different
mechanisms. First, mutations can occur resulting in substitution
of a larger amino acid that may reduce the diameter of the pore
or change the properties of the pore such that the drug does not
bind. Alternatively, mutations in the TM domain may actually
increase the pore diameter such that, if the drug binds, it will not
block the ion channel (Astrahan et al., 2004). The results
presented here are based on our previous study in which we
constructed a virus (SHIVM2) in which the TM domain of Vpu
was replaced with the TM domain/ion channel of the M2
protein of influenza Avirus (Hout et al., 2006). In that study, we
showed that the replication and spread of SHIVM2 were
inhibited by the drug rimantadine. Furthermore, we showed
that SHIVM2 retained the ability to cause disease in macaques.
This suggested that the M2 viroporin could substitute for the
viroporin of Vpu and that anti-viral drugs targeting this domain
could represent a new class of anti-HIV-1 drugs. Previously, we
reported an invariant tryptophan residue at position 23 of the
Vpu protein (McCormick-Davis et al., 2000a). This residue is
approximately at the same position within the Vpu TM domain
Fig. 9. Quantification of the number of viral particles associated with the infected C8166 cells following inoculation with SHIVKU-1bMC33 (C, D) or SHIVVpuA19H (A,
B) in the absence (A, C) or presence of rimantadine. Cells were inoculated with equivalent doses of infectious virus and after 7 days processed for electron microscopy
as described in the Materials and methods section. The number of viral particles associated with 100 cells per virus/treatment was enumerated. (A) The number of viral
particles per cell following inoculation with SHIVVpuA19H. (B) The number of viral particles per cell following inoculation with SHIVVpuA19H and treatment with 25
μM rimantadine. (C) The number of viral particles per cell following inoculation with SHIVKU-1bMC33. (D) The number of viral particles per cell following inoculation
with SHIVKU-1bMC33 and treatment with 50 μM rimantadine.
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instead of the His–X–X–X–Trp motif found in the M2 protein,
the HIV-1 subtype B Vpu has the sequence Ala–X–X–X–Trp.
Interestingly, replacement of M2 His37 with other amino acids
(including alanine) impaired the selectivity of the ion channel
resulting in constant current under neutral or acidic conditions
(Pinto et al., 1992; Wang et al., 1995).
Replacement of the alanine at position 19 of Vpu with a
histidine residue resulted in a protein that was transported to the
same intracellular compartment as the unmodified Vpu and was
still capable of CD4 down-regulation from the cell surface.
Thus, it appeared that structural properties and biological
functions were preserved in the VpuA19H protein. However,
when we constructed an SHIV expressing the Vpu protein, the
SHIVVpuA19H was phenotypically more similar to SHIVM2 than
the parental SHIVKU-1bMC33. First, at concentrations of 25–50
μM rimantadine, SHIVVpuA19H replication was reduced from 80
to 13%, while a concentration of 75–100 μM almost completelyabolished the spread of SHIVVpuA19H in culture. Second,
electron microscopic examination of infected cells treated with
25 μM rimantadine revealed particles accumulated at the
surface of infected cells and within intracellular vesicles, similar
to rimantadine-treated SHIVM2 (Hout et al., 2006).
The results of this study have implications for the structure of
the Vpu transmembrane domain. Recently, the three-dimen-
sional structure of the Vpu TM domain in micelles and bilayer
samples was reported using NMR spectroscopy (Park et al.,
2003). In this study, Vpu adopted a transmembrane α-helix
spanning residues from the isoleucine at position 8 to the valine
at position 25. The helix was found to be kinked slightly in the
middle at the isoleucine at position 17, and there was a 13°
average slant angle of the helix to the membrane normal. These
investigators presented data that the Vpu TM formed oligomeric
structures and presented both tetrameric and pentameric models
of the Vpu TM structure based on their data. In their model, the
invariant tryptophan produced unfavorable clashes unless its
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that the serine at position 23 faced the surrounding lipids while
the isoleucine at position 17 faced the pore lumen. In the model
of amantadine blockage of the M2 ion channel, the histidine and
tryptophan residues at positions 37 and 41 face the pore of the
channel, and their interactions are critical to the function of
pore. Amantadine is thought to act as a surrogate H+ donor, and
interactions with the histidine residues result in blocking of the
pore. Our results provide additional data that the alanine at
position 19 faces the lumen of the Vpu channel as alteration of
this residue to a histidine results in a virus that is sensitive to
rimantadine. It will be of interest to determine if the VpuA19H
protein is an ion channel for protons. If so, it may be a more
simplistic channel than the M2 protein as the side chain of
tryptophan in Vpu is thought to face the surrounding lipids and
thus would not be in a position to form an activation gate like
the M2 protein. The finding of increased rimantadine sensitivity
when compared to SHIVM2 suggests that the pore structure of
Vpu may have a wider diameter than that of the M2 protein such
that the pore structure formed by VpuA19H is more accessible to
rimantadine than VpuM2. It may also be possible that the larger
imidazolium side group of the histidine residue (as opposed to
the methyl group of the alanine residue) may widen the pore
structure formed by VpuA19H and make it more accessible to the
rimantadine.
The M2 protein of influenza virus has two important
functions in the influenza A virus replication cycle (Gonzalez
and Carrasco, 2003). During virus entry by receptor-mediated
endocytosis, acidification of endosomes activates the M2 ion
channel resulting in the influx of H+ into the virus resulting in a
low pH conformational change in the hemagglutinin (HA). This
results in exposure of the fusion peptide domain of the HA,
fusion of the endosomal and viral membranes, and release of the
viral nucleocapsids into the cytoplasm. In addition to its role in
virus entry, the M2 protein is important for transport of the HA
molecule to the cell surface. As there is a gradual drop in the pH
from the rough endoplasmic reticulum (RER) to the trans-Golgi
network (TGN), the M2 protein (based on its orientation)
becomes activated and causes an efflux of H+ from the TGN,
thereby preventing a low pH conformational change of the
newly synthesized HA molecule as it transported to the cell
surface (Sakaguchi et al., 1996; Henkel and Weisz, 1998;
Henkel et al., 1999). It will be of interest to determine if
blocking of the Vpu pore with rimantadine treatment of
SHIVVpuA19H-infected cells will affect the processing of the
HIV-1 envelope glycoprotein in a way similar to that observed
for influenza A virus hemagglutinin (HA).
The results presented here provide additional data to support
a role for the Vpu protein in virion maturation and as a target for
the design of novel anti-HIV-1 drugs. In our previous study
using SHIVM2, which contained the entire TM domain from the
M2 virus, we showed that rimantadine was capable of inhibiting
the replication and spread of this virus in culture. The results in
this study expand on these findings and show that replacement
of a single amino acid within the Vpu TM domain was sufficient
to render the virus susceptible to rimantadine. Taken together,
these studies indicate that rimantadine is capable of interactingwith the pore structure of Vpu protein and that this class of
compounds may serve as the basis for the discovery of novel
rimantadine/amantadine derivatives that interact with the
unmodified Vpu protein. Because we have incorporated this
modified vpu gene in the genetic background of a pathogenic
SHIV, we should be able to determine if rimantadine treatment
of SHIVVpuA19H-inoculated macaques will reduce virus burdens
in macaques and/or this drug will drive the selection of the
mutants that are resistant to rimantadine and result in
accompanying increases in viral loads.
Materials and methods
Cells and viruses
The lymphocyte C8166 cell line was used for transfection of
plasmids to generate viruses as well as indicator cells to
measure infectivity and cytopathicity of the viruses used in this
study. C8166 cells were maintained in RPMI-1640, supple-
mented with 10 mM HEPES buffer pH 7.3, 2 mM glutamine, 5
μg per ml gentamicin, and 10% fetal bovine serum (R10FBS).
HeLa CD4+ cells were used to assess CD4 down-regulation,
and 293 cells were used to assess the intracellular localization of
the unmodified and mutant Vpu proteins and were used in CD4
degradation assays. The derivation of SHIVKU-1bMC33 has been
previously described (McCormick-Davis et al., 2000b; Ste-
phens et al., 2002). The construction and characterization of the
SHIVM2 virus have been previously described (Hout et al.,
2006).
Construction of VpuEGFPA19H
In order to assess the intracellular transport of VpuA19H and
its ability to down-regulate CD4 expression, we constructed an
expression vector in which the VpuA19H was fused to the gene
for EGFP using the same methodology as we used to express
the subtype B and C proteins of HIV-1 as well as four SIVcpz
Vpu proteins (Singh et al., 2003; Pacyniak et al., 2005; Gomez
et al., 2005; Hout et al., 2006). For the site-directed
mutagenesis, we used the plasmid pvpuEGFP and the Quick-
Change Mutagenesis Kit (Stratagene) according to the manu-
facturer's instructions. Two rounds of mutagenesis were
performed using the oligonucleotide 5′-GTAGCAATAATAA-
TACAAATAGTTGTGTGGTCC-3′ (first round) and 5′-GTA-
GCAATAATAATACACATAGTTGTGTGGTCC-3′ (second
round) to alter the alanine residue to a histidine within the
Vpu TM sequence. Clones were isolated, plasmids isolated, and
the entire insert sequenced to determine if the mutations were
introduced as expected and to ensure that no additional changes
were introduced during the mutagenesis. The resulting plasmid,
pvpuEGFPA19H, was digested with KpnI and StuI, the
vpuEGFPA19H gene was isolated by gel electrophoresis and
subcloned into the expression vector pcDNA3.1(+), which was
digested with KpnI and EcoRVas we have previously described
(Singh et al., 2003; Pacyniak et al., 2005; Gomez et al., 2005;
Hout et al., 2006). The sequence of the vpuEGFPA19H gene in
the pcDNA3.1(+) vector was confirmed prior to any expression
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are shown in Fig. 1.
Transfections and laser scanning confocal fluorescence
microscopy analysis
Plasmids expressing VpuEGFP and other fusion proteins
were transfected in human 293 cells to assess their subcellular
localization using a cationic polymer (polyethylenimine)
transfection 5 reagent (ExGen™ 500, MBI Fermentas) using
the manufacturer's protocol. Briefly, 1–3 × 105 cells were
seeded onto cover slips in each well of a 6-well tissue culture
plate 24 h prior to transfection. Transfection was carried out on
cultures that were 50–60% confluent using 4.75 μg plasmid
DNA and 15.5 μl of ExGen™ 500 corresponding to 6
equivalents. Each plasmid DNA sample was diluted in 300 μl
of 150 mM sodium chloride solution separately. Samples were
vortexed gently and immediately centrifuged at low revolution
for a few seconds. Polyethylenimine was then added to the
plasmid DNA solution, mixed with a vortex and allowed to
stand at room temperature for 10 min. The 293 cells were
washed with serum-free media twice, and 3.0 ml of serum-free
DMEM was added. Polyethylenimine/DNA mixture was added
to the cells, and the plate swirled by slow hand rotation for a
couple of seconds. Culture plates were centrifuged at 280 × g
for 5 min and incubated at 37 °C for 30 min. The medium from
transfected cultures was replaced with fresh complete growth
media, and cells were incubated at 37 °C in 5% CO2
atmosphere.
Transfected cells were observed by confocal microscopy so
that fluorescence could be detected from cells in different
optical sections. Transfected cells were grown in 35 mm Petri
dishes and were prepared for confocal microscopy as follows.
Cells were rinsed briefly in phosphate-buffered saline (PBS,
pH 7.2) at room temperature. The cells were fixed in freshly
prepared, ice-cold, 1% paraformaldehyde in 0.13 M in
sodium phosphate pH 7.2 for 2 min. The fixative was
removed, and the cells briefly rinsed in phosphate-buffered
saline. The saline was removed, and one drop of mounting
media was placed on each dish. The mounting media is
composed of 75% glycerol, 25% 0.13 M sodium phosphate
buffer pH 8.0 plus 0.02% n-propyl gallate. A square number
one glass cover slip was placed over each dish. The cells
were imaged with a Zeiss LSM 510 confocal microscope in
the upright configuration. The objective used was a 63× 1.4
n.a. Plan Apochromat. Images were captured at a 12-bit
resolution with a pixel array of 1024 × 1024 and a zoom of
2.0×. The signal was averaged 4 times per line. The EGFP
was excited with light at 488 nm (laser intensity 75% for all
images), and the emitted light was collected after passing
through a 505 nm long pass filter. The amplifier offset and
gain were identical for all images. The detector gain was
decreased from 692 nm to 618 nm for cells expressing
VpuA19HEGFP since the intensity of the signal resulted in
saturation. A Z stack of 20 optical slices was obtained so that
the entire cell was imaged from bottom to top. The pinhole
was set to 96 μm which at this wavelength represents oneairey unit. The optical section had a width of 0.7 μm.
Simultaneous to the acquisition of the confocal signal from
the EGFP, a non-confocal transmitted light image was
obtained to provide a reference point for the EGFP signal.
Individual confocal slices were overlaid onto the grayscale
transmitted light image.
To confirm the presence of the Vpu fusion protein at
different subcellular compartments, a series of co-transfection
studies were performed using vectors expressing either an ER
marker fused to the fluorescent protein DsRed2 (pDsRed2-
ER), a Golgi complex marker fused to a cyano-variant of
EGFP (pECFP-Golgi), or a membrane marker (pECFP-Mem).
293 cells were co-transfected with vectors expressing the
various Vpu fusion proteins and either DsRed2-ER, ECFP-
Golgi, or ECFP-Mem. At 48 h post-transfection, cells were
processed for confocal microscopy as described above, and
cells expressing both proteins identified. Fluorescent digital
images were obtained using a Zeiss LSM510 confocal
microscope equipped with an Argon/2 laser (25 mW) for
the excitation (488 nm, 50% laser power) and detection (band
pass 505–530 nm filter; BP505–530) of EGFP, for the
excitation (458 nm, 100% laser power) and detection (band
pass 475–525 nm filter; BP475–525) of ECFP, and for
excitation (558 nm, 100% laser power) and detection (band
pass 583 nm filter; LP560) of DsRed2. Images were acquired
in Multitrack channel mode (sequential excitation/emission)
with LSM510 (v 3.2) software and a Plan-Apochromat 100×/
1.4 Oil DIC objective with frame size of 2048 × 2048 pixels.
Detector gain was set initially to cover the full range of all
the samples and background corrected by setting the
amplifier gain, and all images were then collected under
the same photomultiplier detector conditions and pinhole
diameter.
Assays for detection of cell surface CD4 and degradation of
CD4
To determine if the VpuEGFPA19H construct was capable of
promoting degradation of CD4 in transfected cells, we
employed HeLa CD4+ cells. Cultures of HeLa CD4+, in
which approximately 80–85% of the cells stained positive for
surface CD4, were recloned to obtain a population of cells in
which N99% of the cells stained positive for cell surface CD4.
Briefly, HeLa CD4+ cells were grown on cover slips and
transfected with pcvpuEGFPA19H as described earlier. At 48
h post-transfection, cells were washed twice with wash buffer
(PBS pH 7.2, containing 2% fetal calf serum and 0.01% NaN3)
and reacted with mouse anti-CD4 (clone SFCI12T4D11CD4,
Beckman-Coulter, 1:500 dilution) for 45 min. After the
incubation, cover slips were washed three times and incubated
with rhodamine-conjugated secondary antibody (goat anti-
mouse, Chemicon, 1:50 dilution) for 35 min followed by
washing five times in buffer without serum. Cells were then
fixed in 1% formalin for 10 min, washed twice, equilibrated
with anti-fade buffer, and mounted on microscope glass slides
using Anti-fade (Molecular Probes, Oregon). Cells were
immediately observed under a fluorescent microscope (Nikon
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rhodamine filters (for visualization of CD4 staining). All
staining procedures were performed on ice and in the dark.
HeLa CD4+ cells transfected with EGFP alone served as control
for down-regulation of CD4 and cultures of HeLa CD4+ cells
treated with wash buffer instead of primary antibody served as
negative control for CD4 staining. A minimum of 400 EGFP
expressing cells were counted.
In addition to detection of CD4 on the cell surface of
transfected HeLa CD4+ cells, co-transfection experiments were
performed using vectors expressing each VpuEGFP fusion
protein and a vector expressing the human CD4 protein
(pCMV4Neo; Goldsmith et al., 1995). 293 cells were
transfected with Vpu fusion and pCMV4Neo vectors at a 3:1
ratio, respectively. This was to ensure that all cells transfected
with the CD4 expressing vector were also transfected with the
vector expressing the Vpu fusion proteins. At 48 h post-
transfection, cells were starved for methionine and then
radiolabeled with 500 μCi 35S-methionine/cysteine for 1 h.
The radiolabel was removed and chased with 100× cold
methionine/cysteine for 4 h. Cells were lysed in radioimmuno-
precipitation assay (RIPA; 50 mM Tris–HCl, pH 7.5; 0.2%
SDS; 0.5% sodium deoxycholate, 5 mM EDTA; 50 mM NaCl)
buffer, lysates prepared and the CD4 immunoprecipitated using
a rabbit anti-CD4 (sc-7219; Santa Cruz Biotechnology) and
protein A Sepharose (PAS). Immunoprecipitates were collected,
washed three times with 1× RIPA, and analyzed by SDS-PAGE
(10% gel). Controls included co-transfection with pcEGFP
(expressing on EGFP) as negative control for CD4 degradation
and co-transfection with a pcvpuEGFP (expressing the subtype
B VpuEGFP fusion protein) as a positive control for CD4
degradation.
Construction of SHIVVpuA19H
A virus designated as SHIVVpuA19H was constructed in
which the alanine residue at position 19 in parental virus
SHIVKU-1bMC33 was changed to a histidine residue. Plasmid
pUC19ΔSNvpu12, containing the SphI to KpnI fragment of
SHIVKU-1bMC33 in pUC-19 (and coding for the tat, rev, vpu,
and 5′ end of env), was used for the site-directed mutagenesis
studies of the Vpu TM. The plasmid used was pUC19-
ΔSNvpu12 and the Quick-Change Mutagenesis Kit (Strata-
gene) according to the manufacturer's instructions. Two rounds
of mutagenesis were performed using the oligonucleotide 5′-
GTAGCAATAATAATACAAATAGTTGTGTGGTCC-3′ (first
round) and 5′-GTAGCAATAATAATACACATAGTTGTGT-
GGTCC-3′ (second round) to alter the alanine residue to a
histidine within the Vpu TM sequence. Clones were isolated,
plasmids isolated, and the entire insert sequenced to determine
if the mutations were introduced as expected and to ensure that
no additional changes were introduced during the mutagenesis.
The plasmid, designated as pUC19ΔSNvpu, was digested to
completion with SphI and KpnI, the 450 base pair insert
isolated and ligated into p3′SHIVKU-1bMC33 using T4 DNA
ligase, which was also digested with KpnI and SphI and gel
purified. The resulting plasmid, p3′SHIVVpuA19H, was se-quenced to ensure that no insertions or deletions had occurred
during the cloning process. The SHIVVpuA19H virus was
generated by digestion of p5′-SHIV-4 and p3′SHIVVpuA19H
with SphI, ligation of the two plasmids together with T4 DNA
ligase, and transfection into C8166 cells as previously
described (McCormick-Davis et al., 2000b; Stephens et al.,
2002; Hout et al., 2004b). Stocks of virus were prepared and
stored at −86 °C.
Immunoprecipitations
To determine if Vpu proteins were expressed in
SHIVVpuA19H-inoculated cultures, C8166 cells were inoculat-
ed with 103 TCID of either SHIVVpuA19H or SHIVKU-1bMC33.
At 7 days post-infection, the medium was removed, and
infected cells were incubated in methionine/cysteine-free
Dulbecco's modified Eagle's medium (DMEM) for 2 h.
The cells were then radiolabeled for 12 h with 500 μCi per
ml of 35S-Translabel (methionine and cysteine, ICN Biomed-
ical, Costa Mesa, CA). Vpu proteins were immunoprecipi-
tated from the cell lysates using an anti-Vpu serum as
previously described (McCormick-Davis et al., 2000b; Singh
et al., 2003). Lysates were subjected to centrifugation to
remove nuclei prior to the addition of antibody. Cell lysates
were incubated with antibody for 16 h at 4 °C, and
immunoprecipitates were collected on protein A Sepharose.
The beads were washed three times with RIPA buffer, and the
samples resuspended in sample reducing buffer and boiled.
Proteins were separated by SDS-PAGE and visualized by
standard autoradiographic techniques.
Pulse-chase analysis of viral proteins
To analyze the viral proteins synthesized and released from
cells, C8166 cells were inoculated with 104 TCID50 of either
SHIVVpuA19H or SHIVKU-1bMC33. At 7 days post-inoculation,
the medium was removed, and infected cells were incubated
in methionine/cysteine-free Dulbecco's modified Eagle's
medium (DMEM) for 2 h. The cells were then radiolabeled
for 30 min with 1 mCi per ml of 35S-Translabel (methionine
and cysteine, ICN Biomedical, Costa Mesa, CA) and the
radiolabel chased for various periods of time in DMEM
containing 100× unlabeled methionine/cysteine. SHIV pro-
teins were immunoprecipitated from the cell culture medium
and infected cell lysates using plasma pooled from several
rhesus monkeys infected previously with non-pathogenic
SHIV-4. Briefly, the cell culture medium was clarified
(16,000 × g) for 2 min. The supernatant was transferred
and made 1× with respect to cell lysis buffer (50 mM Tris–
HCl, pH 7.5; 50 mM NaCl; 0.5% deoxycholate; 0.2% SDS;
10 mM EDTA), and SHIV proteins were immunoprecipitated
with 10 μl of the serum described above. For immunopre-
cipitation of cell-associated SHIV proteins, cell lysates were
prepared as described previously (Stephens et al., 1995, 1997,
2002; McCormick-Davis et al., 2000b; Hout et al., 2004b)
prior to incubation with antiserum. Lysates were subjected to
centrifugation to remove nuclei prior to the addition of
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with antibody for 16 h at 4 °C. All immunoprecipitates were
collected on protein A Sepharose, the beads washed three
times with RIPA buffer, and the samples resuspended in
sample reducing buffer. Samples were boiled and the SHIV
specific proteins analyzed by SDS-PAGE. Proteins were then
visualized by standard autoradiographic techniques.
p27 assays
p27 growth curve assays were used to assess replication
kinetics of the SHIVVpuA19H or parental SHIVKU-1bMC33.
Cultures of 106 C8166 cells were inoculated with equivalent
amounts (10 ng) of cell-free virus stocks for 2 h. At the end of 2
h, the cells were centrifuged at 400 × g for 10 min, and the pellet
washed with 10 ml of medium. Cells were washed two
additional times. The cells were resuspended in RPMI-1640
supplemented with 10% FBS and antibiotics, and this was
considered the 0 time point of the assay. Cultures were
incubated at 37 °C, and aliquots of the culture were removed
at 0, 1, 3, 5, 7, and 10 days. The culture medium was separated
from the cells by centrifugation, and the culture supernatants
assayed for p27 according to the manufacturer's instructions
(Coulter). For assays involving rimantadine, the drug was
freshly prepared in RPMI-1640 medium as 10 mM stocks and
filter sterilized prior to addition to cultures. Drug was added to
cultures at the 0, 3, 6, and 9 days time points.
Electron microscopy
To determine the site of intracellular maturation, infected
cells were examined by electron microscopy. Cultures of C8166
cells were inoculated with SHIVKU-1bMC33 or SHIVVpuA19H at a
multiplicity of infection (M.O.I) of 0.01. Cells were incubated
for 7 days at which time cells were pelleted at 400 × g for 10
min. Cells were washed three times with 10 ml of phosphate-
buffered saline (pH 7.4) and then fixed in 2% glutaraldehyde
overnight at 4 °C. Cells were postfixed in 1% osmium tetroxide
(OsO4) for 1 h. The cells were washed twice with water and
dehydrated through a series of alcohols (30–100%) followed by
embedding in Embed 812 resin. Thin sections were cut at 80 Å,
stained with uranyl acetate and lead citrate, and examined under
a JEOL 100CXII transmission electron microscope. The
number of virus particles associated with infected cells (either
at the surface or within the cell) was enumerated for 100 cells.
Data were analyzed by planned comparisons using unpaired t
test. Data from the untreated and 25 μM treated SHIVVpuA19H-
infected cultures was compared to 50 μM SHIVKU-1bMC33-
infected cultures.
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